Closely watched Parkinson's drug from Biogen, Denali comes up short
Biogen and Denali Therapeutics have announced that their experimental Parkinson's disease drug, BIIB122, has failed a key clinical trial. The mid-stage trial showed no significant improvement in slowing disease progression compared to a placebo. Denali plans to continue independent research on a subset of patients with a specific genetic variant linked to Parkinson's.
- ▪The drug was developed through a partnership formed in 2020 between Biogen and Denali Therapeutics.
- ▪The trial involved nearly 650 participants and aimed to assess the drug's effectiveness against a placebo.
- ▪Despite some exploratory analyses indicating engagement with the harmful enzyme, the overall results were disappointing.
Hacker News (Newest) files mainly under programming. We currently carry 5,306 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | BioPharma Dive |
| Canonical URL | https://www.biopharmadive.com/news/biogen-denali-parkinsons-trial-failure-lrrk2/820961/ |
| Publication time | Wed, 27 May 2026 18:59:52 +0000 |
| Retrieval time | 2026-05-27T19:08:02.822Z |
| Last seen | 2026-05-27T19:08:02.822Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 466Wl0YjWFWO |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
An article from Parkinson’s drug from Biogen, Denali comes up short High-level results have led the companies to scrap a mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients. Published May 22, 2026 Jacob Bell Lead Reporter Share Copy link Email LinkedIn X/Twitter Facebook Print License Add us on Google Biogen and Denali Therapeutics have been working on a Parkinson's disease drug under an alliance formed in 2020. Getty Images The outlook for an experimental Parkinson’s disease drug dimmed on Thursday with the announcement that it had failed a key clinical trial.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at BioPharma Dive.
Discussion
0 commentsMore from BioPharma Dive
